2 Big Risks Threatening Celgene

While the future of Celgene looks bright in terms of the company's promising pipeline, its present is facing some serious threats. In this video, Fool health-care analyst David Williamson tells investors how the company's present success is absolutely tied to its two key drugs, Revlimid and Vidaza. David highlights the threats to these drugs both in the form of generics, as well as very fierce competition.

Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today simply click here now.

The article 2 Big Risks Threatening Celgene originally appeared on Fool.com.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.